Clinical Trial to Evaluate the Efficacy and Safety of Nexpowder™ for Diverticular Bleeding in the Lower Gastrointestinal Tract

Not Yet Recruiting

Trial opening soon.

Key information

Conditions

Lower Gastrointestinal Bleeding Digestive System Diseases Diverticular Bleeding Diverticular Diseases Gastroenteritis Gastrointestinal Diseases

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Chungbuk National University Hospital, Cheongju-si, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adults aged 19 years or older at the time of screening
Patients diagnosed with diverticular bleeding

Exclusion criteria

Patients diagnosed with upper gastrointestinal bleeding

Treatment and study plan

Nexpowder™

Device

Nexpowder™ hemostatic powder

Primary outcomes

Rebleeding rate

Time frame: 30 days post treatment

30 days after successful endoscopic hemostasis

Secondary outcomes

Hemostasis rate

Time frame: Immediately after the procedure

Hemostasis rate
Rebleeding rate

Time frame: 7 days post treatment

Rebleeding rate

Sponsors and collaborators

Lead sponsor

Next Biomedical Co., Ltd.

Industry

Registry information

Official study title

Clinical Trial to Evaluate the Efficacy and Safety of Nexpowder™ for Diverticular Bleeding in the Lower Gastrointestinal Tract: A Prospective, Multi-Center, Single-Arm, Open-Label, Pilot Clinical Trial

Important dates

Study start: 2025
Primary completion: 2027
Study completion: 2027
First posted: Apr 23, 2025
Registry last updated: Apr 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting